Who is sponsoring NCT04801199?

NCT04801199 is sponsored by Cadila Pharnmaceuticals.

What drugs are being tested in NCT04801199?

Interventions in NCT04801199: CPL-2009-0031 140 mg, Sitagliptin 100mg.

What condition does NCT04801199 study?

NCT04801199 studies Uncontrolled Type 2 Diabetes Mellitus.

Is NCT04801199 still recruiting?

NCT04801199 is currently completed. Last updated 17 August 2021.

Last reviewed 2021-08-17 · How we verify

NCT04801199

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus

Completed Phase 3 Last updated 17 August 2021

What this trial tests

Phase 3 trial testing CPL-2009-0031 140 mg in Uncontrolled Type 2 Diabetes Mellitus in 355 participants. Completed in 11 February 2021.

Timeline

26 January 2020

Primary endpoint
13 January 2021

11 February 2021

Quick facts

Lead sponsor	Cadila Pharnmaceuticals
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	355
Start date	26 January 2020
Primary completion	13 January 2021
Estimated completion	11 February 2021
Sites	12 locations across India

Drugs / interventions tested

CPL-2009-0031 140 mg — full drug profile →
Sitagliptin 100mg — full drug profile →

Conditions studied

Uncontrolled Type 2 Diabetes Mellitus — all drugs for Uncontrolled Type 2 Diabetes Mellitus →

Sponsor

Cadila Pharnmaceuticals — full company profile →

Who can join

Adults 18 to 65, any sex, with Uncontrolled Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is a Phase-III, Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled clinical trial to determine the efficacy, safety, and tolerability of oral CPL-2009-0031 140 mg in comparison with Sitagliptin 100 mg in patients with Uncontrolled Type-2 Diabetes Mellitus (T2DM).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Cadila Pharnmaceuticals trials

Trials by the same sponsor.

NCT04353518 — Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19 · Phase 3 · unknown
NCT04358809 — Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill · Phase 3 · unknown
NCT04347174 — A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients · NA · completed
NCT05174598 — A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With · Phase 3 · completed
NCT00694915 — Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04801199 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cadila Pharnmaceuticals
Last refreshed: 17 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04801199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing